Cargando…

Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease

BACKGROUND/AIMS: We assessed the effectiveness of anti-TNF agents and its associated factors to prevent endoscopic and clinical postoperative recurrence (POR) in Crohn’s disease (CD). METHODS: From a prospectively-maintained database, we retrieved 316 CD patients who underwent intestinal resection (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buisson, Anthony, Cannon, Lisa, Umanskiy, Konstantin, Hurst, Roger D., Hyman, Neil H., Sakuraba, Atsushi, Pekow, Joel, Dalal, Sushila, Cohen, Russell D., Pereira, Bruno, Rubin, David T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344250/ https://www.ncbi.nlm.nih.gov/pubmed/34333909 http://dx.doi.org/10.5217/ir.2021.00018

Ejemplares similares

Low Skeletal Muscle Index Adjusted for Body Mass Index Is an Independent Risk Factor for Inflammatory Bowel Disease Surgical Complications
por: Berger, Matthew, et al.
Publicado: (2020)

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
por: Ayoub, Fares, et al.
Publicado: (2022)

A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis
por: Zafer, Maryam, et al.
Publicado: (2021)

Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease
por: Micic, Dejan, et al.
Publicado: (2017)

Inflammation in the proximal colon is a risk factor for the development of colorectal neoplasia in inflammatory bowel disease patients with primary sclerosing cholangitis
por: Jamil, Omar K., et al.
Publicado: (2023)

Caring for Patients with Rectal Cancer During the COVID-19 Pandemic
por: Skowron, Kinga B., et al.
Publicado: (2020)

Parastomal Variceal Bleeding Attributed to Obstructive Pathology Successfully Treated by Percutaneous Variceal Embolization
por: Tomizawa, Yutaka, et al.
Publicado: (2014)

Factors associated with poor compliance amongst hospitalized, predominantly adolescent pediatric Crohn’s disease patients
por: Cohen, Nathaniel A., et al.
Publicado: (2022)

Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion
por: Wang, Jingzhou, et al.
Publicado: (2018)

Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
por: Yu, Jongwook, et al.
Publicado: (2022)

Two Complex Cases of Hermansky-Pudlak Syndrome Highlight a Potential Biologic Explanation for an Associated Crohn’s Disease Phenotype
por: Sofia, M. Anthony, et al.
Publicado: (2017)

Risk Factors for Postoperative Recurrence of Crohn’s Disease
por: Khoshkish, Shayan, et al.
Publicado: (2012)

Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention
por: Pagnini, Cristiano, et al.
Publicado: (2021)

Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics
por: Akiyama, Shintaro, et al.
Publicado: (2021)

Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates
por: Eberhardson, Michael, et al.
Publicado: (2022)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Long‐term effectiveness of ustekinumab comparable to antitumor necrosis factor agents in patients with Crohn's disease
por: Shiga, Hisashi, et al.
Publicado: (2022)

Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis
por: Cañete, Fiorella, et al.
Publicado: (2020)

Anti-tumor Necrosis Factor Therapy for Crohn Disease: Friend or Foe to the Surgeon?
por: Kim, Hungdai
Publicado: (2015)

Use of Vitamin D With Anti-Tumor Necrosis Factor Therapy for Crohn’s Disease
por: Bafutto, Mauro, et al.
Publicado: (2020)

Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody
por: Pichler, Judith, et al.
Publicado: (2020)

Risk Factors for Postoperative Recurrence in Korean Patients with Crohn’s Disease
por: Kim, Sung Bae, et al.
Publicado: (2020)

Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis
por: Cohen, Nathaniel A., et al.
Publicado: (2022)

Could Early Anti-Tumor Necrosis Factor Therapy Change the Prognosis of Crohn's Disease?
por: Ye, Byong Duk
Publicado: (2014)

Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls
por: Kotze, Paulo Gustavo, et al.
Publicado: (2017)

Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease
por: Netz, Uri, et al.
Publicado: (2017)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn’s Disease
por: Thurlapati, Aswani, et al.
Publicado: (2021)

Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s disease
por: Li, Kangrong, et al.
Publicado: (2023)

Risk factors for postoperative recurrence of Crohn’s disease with emphasis on surgical predictors
por: Gklavas, Antonios, et al.
Publicado: (2017)

Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn’s disease
por: Alfaro, Ignacio, et al.
Publicado: (2019)

The Efficacy of Anti-Tumor Necrosis Factor Alpha for Symptomatic Stricturing Small Bowel Crohn’s Disease
por: Alourfi, Mansour, et al.
Publicado: (2020)

The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn’s Disease Patients
por: Altuwaijri, Mansour, et al.
Publicado: (2022)

Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
por: Oh, Kyunghwan, et al.
Publicado: (2023)

Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
por: Moroi, Rintaro, et al.
Publicado: (2019)

Endoscopic and Pathologic Changes of the Upper Gastrointestinal Tract in Crohn's Disease
por: Sakuraba, Atsushi, et al.
Publicado: (2014)

Multiple Autoimmune Skin Manifestations in a Patient with Crohn's Disease Treated with a Tumor Necrosis Factor-Alpha Blocker
por: Zattra, Edoardo, et al.
Publicado: (2015)

Altered pattern of tumor necrosis factor-alpha production in peripheral blood monocytes from Crohn's disease
por: Loganes, Claudia, et al.
Publicado: (2016)

Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies
por: Bamberger, Sarah, et al.
Publicado: (2016)

Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease
por: Hiraoka, Sakiko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_droiu0atm7lv2ddoo09lijm9c9